Clinical trial NCT00665223 (phase 3, status: completed)
Conditions: huntington's disease
ICD codes: G10
Drugs: acr16, placebo
SMILES: CCCN1CCC(CC1)C1=CC=CC(=C1)S(C)(=O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Able to provide written Informed Consent prior to any study related procedure.

          -  Huntington's disease diagnosed with the aid of clinical features and a positive family
             history and/or the presence of ≥ 36 CAG repeats in the Huntington gene.

          -  Male or female age ≥ 30 years.

          -  Willing and able to take oral medication and able to comply with the study specific
             procedures.

          -  Ambulatory, being able to travel to the assessment centre, and judged by the
             Investigator as likely to be able to continue to travel for the duration of the study.

          -  Availability of a caregiver or family member to accompany the patient.

          -  A sum of ≥ 10 points on the mMS at the screening visit.

          -  For patients taking allowed antipsychotic medication, the dosing of medication must
             have been kept constant for at least 6 weeks before randomisation. The allowed
             antipsychotic medication is Amisulpride, Haloperidol, Olanzapine, Risperidone,
             Sulpiride, or Tiapride.

          -  For patients taking allowed antidepressant or other psychotropic medication, the
             dosing of medication must have been kept constant for at least 6 weeks before
             randomisation.

          -  Willing to provide a blood sample for CAG analysis (where CAG result is not already
             available).

          -  In France only, the patient must be affiliated to a social security system or be a
             beneficiary of such a system.

        Exclusion Criteria:

          -  Unable to give written informed consent.

          -  Treatment with any non-allowed antipsychotic medication within 12 weeks of
             randomisation. The non-allowed antipsychotic medication is any medication other than
             Amisulpride, Haloperidol, Olanzapine, Risperidone, Sulpiride, or Tiapride.

          -  Treatment with the antidepressants Fluoxetine or Paroxetine within 6 weeks of
             randomisation.

          -  Use of Tetrabenazine within 12 weeks of randomisation, or at any time during the study
             period.

          -  Treatment with any investigational product within 4 weeks of randomisation.

          -  Use of tricyclic antidepressants, class I antiarrhythmics, and strong CYP2D6
             inhibitors such as Ajmalicine, Chinidin/Quinidine and Ritonavir, within 6 weeks of
             randomisation.

          -  Patients previously included into this study.

          -  A prolonged QTc interval at screen (defined as a QTc interval of > 450 msec for males
             or > 470 msec for females), or other clinically significant heart conditions.

          -  Creatinine clearance <40mL/min as measured at the screening visit.

          -  Any clinically significant, abnormal, baseline laboratory result which in the opinion
             of the Investigator, affects the patients' suitability for the study or puts the
             patient at risk if he/she enters the study.

          -  Clinically significant hepatic or renal impairment.

          -  Patients with a history of epilepsy or a history of seizure(s) of unknown cause.

          -  Severe intercurrent illness, which, in the opinion of the Investigator, may put the
             patient at risk when participating in the trial or may influence the results of the
             trial or affect the patients' ability to take part in the trial.

          -  Alcohol and/or drug abuse as defined by DSM IV-TR criteria for substance abuse - this
             includes the illicit use of cannabis within the last 12 months.

          -  Patients with suicidal ideation, defined as a positive score on criteria for major
             depressive episode, item A9 on the DSM-IV-TR criteria for a Major Depressive Episode.

          -  Females who are pregnant or lactating.

          -  Females who are of child bearing potential and not taking adequate contraceptive
             precautions are excluded from the trial. Females of child bearing potential taking
             acceptable contraceptive precautions can be included.

          -  Known allergy to any ingredients of the trial medication or placebo.

          -  Any previous participation in a clinical study with ACR16.

          -  Patients currently receiving deep brain stimulation.

          -  Patients with a history of surgical procedures aiming to improve the symptoms of
             Huntington's disease, such as neural transplantations, lesions of the central nervous
             system, infusions of neurotrophic agents or previous attempts of deep brain
             stimulation.